PT  - JOURNAL ARTICLE
AU  - Hardy, Céline S. C.
AU  - Razavi, Ali
AU  - Nunez, Natalie
AU  - Fitzmaurice, William
AU  - Dave, Loma
AU  - Slutzky, Amy R.
AU  - Vanderbeck, Kaitlin
AU  - Farah, Ramsay
TI  - Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans: A scoping review
AID  - 10.1101/2024.10.23.24316006
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.23.24316006
4099  - http://medrxiv.org/content/early/2024/10/28/2024.10.23.24316006.short
4100  - http://medrxiv.org/content/early/2024/10/28/2024.10.23.24316006.full
AB  - This review summarizes the immunohistochemical profiles of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) as reported by primary literature in the past 10 years. 63 studies were included in the review, with staining information for a total of 99 unique IHC markers reported. The most commonly reported stains were CD34, SMA, S100, and FXIIIa. Most studies applied IHC either to explore descriptive features of DF or DFSP or to determine their utility in diagnostic identification of the lesions. A number of studies applied novel biomarkers which may hold promise for distinguishing DF and DFSP, namely WT1, Cx43, LSP-1, and PHH3, which demonstrated considerable expression differences between the two lesions. This review highlights the need for validation of existing and emerging IHC markers for the diagnosis of DF and DFSP.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData supporting the findings of this study are available within the article and/or its supplementary material.